CNW Stock Overview
co.don AG, a biopharmaceutical company, develops, produces, and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||€0.58|
|52 Week High||€2.56|
|52 Week Low||€0.25|
|1 Month Change||-11.59%|
|3 Month Change||-41.41%|
|1 Year Change||-77.34%|
|3 Year Change||-92.35%|
|5 Year Change||-96.63%|
|Change since IPO||-99.05%|
Recent News & Updates
|CNW||DE Biotechs||DE Market|
Return vs Industry: CNW underperformed the German Biotechs industry which returned -3% over the past year.
Return vs Market: CNW underperformed the German Market which returned -20.8% over the past year.
|CNW Average Weekly Movement||32.7%|
|Biotechs Industry Average Movement||8.7%|
|Market Average Movement||5.6%|
|10% most volatile stocks in DE Market||10.4%|
|10% least volatile stocks in DE Market||2.8%|
Stable Share Price: CNW is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 33% a week.
Volatility Over Time: CNW's weekly volatility has increased from 19% to 33% over the past year.
About the Company
co.don AG, a biopharmaceutical company, develops, produces, and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. It offers Spherox, a three dimensional chondrocyte product that is used to treat cartilage defects in adult knee joints; and co.don chondrosphere for the treatment of cartilage defects in the hip, ankle, shoulder and elbow, and knees of younger patients. The company serves accident and orthopedic surgeons.
co.don Fundamentals Summary
|CNW fundamental statistics|
Is CNW overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CNW income statement (TTM)|
|Cost of Revenue||€1.85m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 30, 2022
|Earnings per share (EPS)||-0.35|
|Net Profit Margin||-95.09%|
How did CNW perform over the long term?See historical performance and comparison
Is CNW undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CNW?
Other financial metrics that can be useful for relative valuation.
|What is CNW's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CNW's PS Ratio compare to its peers?
|CNW PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: CNW is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (4.5x).
Price to Earnings Ratio vs Industry
How does CNW's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Sales vs Industry: CNW is good value based on its Price-To-Sales Ratio (1.6x) compared to the German Biotechs industry average (5.8x)
Price to Sales Ratio vs Fair Ratio
What is CNW's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.6x|
|Fair PS Ratio||13.2x|
Price-To-Sales vs Fair Ratio: CNW is good value based on its Price-To-Sales Ratio (1.6x) compared to the estimated Fair Price-To-Sales Ratio (13.2x).
Share Price vs Fair Value
What is the Fair Price of CNW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CNW (€0.58) is trading below our estimate of fair value (€21.82)
Significantly Below Fair Value: CNW is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is co.don forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score6/6
Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNW is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.01%).
Earnings vs Market: CNW is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CNW is expected to become profitable in the next 3 years.
Revenue vs Market: CNW's revenue (28.3% per year) is forecast to grow faster than the German market (4.7% per year).
High Growth Revenue: CNW's revenue (28.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CNW's Return on Equity is forecast to be very high in 3 years time (43.7%).
Discover growth companies
How has co.don performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CNW is currently unprofitable.
Growing Profit Margin: CNW is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CNW is unprofitable, and losses have increased over the past 5 years at a rate of 19.8% per year.
Accelerating Growth: Unable to compare CNW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).
Return on Equity
High ROE: CNW has a negative Return on Equity (-53.07%), as it is currently unprofitable.
Discover strong past performing companies
How is co.don's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CNW's short term assets (€9.5M) exceed its short term liabilities (€3.0M).
Long Term Liabilities: CNW's short term assets (€9.5M) exceed its long term liabilities (€5.8M).
Debt to Equity History and Analysis
Debt Level: CNW has more cash than its total debt.
Reducing Debt: Insufficient data to determine if CNW's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CNW has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CNW has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is co.don current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CNW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CNW's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CNW's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CNW's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CNW has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Tilmann Bur (57 yo)
Mr. Tilmann Bur has been the Member of Executive Board of co.don AG since June 1, 2019 and serves as its Chief Executive Board and served as its Chief Operating Officer until January 2020. Mr. Bur is an in...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Tilmann's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Tilmann's compensation has increased whilst the company is unprofitable.
Experienced Board: CNW's board of directors are considered experienced (9.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.2%.
co.don AG's employee growth, exchange listings and data sources
- Name: co.don AG
- Ticker: CNW
- Exchange: XTRA
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €15.500m
- Shares outstanding: 26.72m
- Website: https://www.codon.de
Number of Employees
- co.don AG
- Warthestraße 21
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/10 00:00|
|End of Day Share Price||2022/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.